Journal of intensive care medicine · 2026
Vasopressin-Based Versus Norepinephrine-Based Strategy in Vasoplegic Syndrome After Cardiac Surgery: A Randomized Controlled Trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cui Huixin, Meng Yanhai, Peng Shuyi, Fan Shangpin, Li Lulu, Li Zemeng, Zhang Yanbo
Аннотация
BackgroundVasoplegic syndrome (VS) is a prevalent complication associated with cardiac surgery that is typically managed with norepinephrine (NE). We conducted a comparative analysis of clinical and physiological effects of vasopressin (VP)-based strategy versus an NE-based strategy as first-line management for VS following cardiopulmonary bypass (CPB).MethodsThis single-center, randomized controlled trial included 90 patients who underwent VS following CPB. Patients were randomized to a VP-based strategy (0.01-0.1U/min) or an NE-based strategy (0.01-0.1μg/kg/min), with standardized rescue NE allowed in both groups if hemodynamic targets were not met. The primary outcome was the length of hospital stay. Secondary outcomes included hemodynamic stability, lactate clearance, cardiac biomarkers, left ventricular ejection fraction (LVEF), and endocrine markers (copeptin and Arginine Vasopressin(AVP)).ResultsThe VP-based strategy significantly reduced the length of hospital stays compared to NE-based (Median 7.0 days [IQR 6.0-8.0] vs Median 8.0 days [IQR 7.0-11.0]; Per-protocol p = .0036). Patients treated with VP achieved higher mean arterial pressure (MAP) and systemic vascular resistance index (SVRI) at 12 and 24 h (P < .05). Furthermore, the VP-based group showed faster lactate normalization and a more pronounced reduction in cardiac biomarkers. Endocrine markers (copeptin and AVP) peaked significantly higher in the VP-based group but did not correlate with clinical outcomes (|r| < .15, p > .05). Adverse event rates were balanced between groups.ConclusionA VP-based strategy provided effective hemodynamic stabilization and is associated with shorter hospital stays compared to NE-based strategy in patients with VS following cardiac surgery. While NE continues to be effective, these findings suggest VP may be considered a viable early alternative or adjunctive vasopressor strategy for managing VS in the post-operative setting.